COMMUNIQUÉS West-GlobeNewswire

Wholeview Wellness Joins the Lumina Therapy Alliance, Expanding Access to In-Person Addiction-Focused Psychotherapy for Employees and Their Families
22/12/2025
NEW YORK, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Lumina Therapy Alliance , the nation’s leading collective of highly vetted, in-person mental health practices, is proud to announce that Wholeview Wellness , the boutique, out [...]
Greenwich LifeSciences Provides Additional Updates on FLAMINGO-01 and Corporate Strategy
22/12/2025
STAFFORD, Texas, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
Biosplice Therapeutics Announces First Patient Dosed in Investigator‑Initiated Phase 1 Clinical Trial of Cirtuvivint and Olaparib in BRCA/HRD Platinum‑Resistant Ovarian Cancer
22/12/2025
Study at the University of Colorado Anschutz Cancer Center builds on preclinical data showing that cirtuvivint plus PARP inhibition overcame resistance in preclinical models of high‑grade serous ovarian cancer SAN DIEGO [...]
Abbisko Therapeutics’ CSF-1R Inhibitor Pimicotinib Approved by the China NMPA, Addressing the Treatment Gap for Tenosynovial Giant Cell Tumor
22/12/2025
Based on the positive global Phase III MANEUVER study, the National Medical Products Administration (NMPA) has granted the world’s first regulatory approval for pimicotinib, the first domestically developed systemic [...]
Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved
22/12/2025
HAIFA, Israel, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Pluri, Inc. (“Pluri”, the “Company”, “we” or “us”) (Nasdaq, TASE: PLUR), a leading biotechnology company leveraging its proprietary platform for cell-based solutions [...]
Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal
22/12/2025
Results Underscore PRP Candidacy as a Disruptor of the Tumor Microenvironment MELBOURNE, Australia, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a [...]
Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
22/12/2025
Enrollment Completed in C-BEYOND Phase 3 Trial with More Than 880 HCV Treatment-Naïve Patients in US and Canada C-BEYOND Topline Results Expected Mid-2026 C-FORWARD Phase 3 Trial, Conducted Outside North America, [...]
Secura Bio Provides Corporate Update and Highlights Progress in its Phase 3 TERZO Study
22/12/2025
Terzo remains on track for an interim data readout in early 2027, based on enrollment to date Achieved >30% annual growth in U.S. net sales of COPIKTRA™ through November BERKELEY HEIGHTS, N.J., Dec. 22, 2025 (GLOBE [...]
Tilray Brands to Announce Second Quarter Fiscal Year 2026 Financial Results on January 8, 2026
22/12/2025
NEW YORK and LEAMINGTON, Ontario, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of [...]
FDA approves Roche’s Lunsumio VELO™ for subcutaneous use in relapsed or refractory follicular lymphoma
22/12/2025
Lunsumio VELO reduces administration time from 2-4 hours to approximately one minute Availability of Lunsumio VELO allows treatment aligned to people’s clinical needs and personal preferences Approval supported by data [...]
Ipsen élargit son portefeuille de produits en développement précoce avec un conjugué anticorps-médicament innovant développé par Simcere Zaiming
22/12/2025
Ipsen obtient les droits mondiaux exclusifs, en dehors de la Grande Chine, pour le développement, la fabrication et la commercialisation de SIM0613, un conjugué anticorps-médicament ciblant le récepteur LRRC15. SIM0613 [...]
Ipsen expands early development pipeline with Simcere Zaiming’s innovative antibody drug conjugate
22/12/2025
Ipsen gains exclusive global rights, outside of Greater China, for development, manufacturing and commercialization of SIM0613, a LRRC15-targeting antibody-drug conjugate SIM0613 is optimally designed for superior tumor [...]
Alvotech announces European launch of first-in-market biosimilar to Simponi® (golimumab) globally by partner Advanz Pharma
22/12/2025
Introduction of AVT05 supported by NHS England tender award in the United Kingdom REYKJAVIK, Iceland, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the [...]
SAFE, PARRAIN DE LA XIIème CONFERENCE INTERNATIONALE MAMMI EN ITALIE
22/12/2025
SAFE, PARRAIN DE LA XII ème CONFERENCE INTERNATIONALE MAMMI EN ITALIE Présentation de sa technologie Sycamore lors d'une intervention chirurgicale en direct Fleurieux-sur-l’Arbresle – France – 22 décembre 2025 – 8h - [...]
SAFE, SPONSOR OF THE 12TH MAMMI INTERNATIONAL CONFERENCE IN ITALY
22/12/2025
SAFE, SPONSOR OF THE 12TH MAMMI INTERNATIONAL CONFERENCE IN ITALY Presentation of its Sycamore technology during a live surgical procedure Fleurieux-sur-l’Arbresle – France – December 22, 2025 – 8am - Safe (FR001400ZU25 [...]
Alvotech announces European launch of first-in-market biosimilar to Simponi® (golimumab) globally by partner Advanz Pharma
22/12/2025
Introduction of AVT05 supported by NHS England tender award in the United Kingdom REYKJAVIK, ICELAND (December 22, 2025) — Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and [...]
Windward Bio Expands Immunology Pipeline With WIN027, a Long-Acting, Clinical-Stage Bispecific Targeting TSLP and IL-13
22/12/2025
Windward Bio and Qyuns Therapeutics announce licensing agreement for WIN027, a highly potent, long-acting bispecific antibody with best-in-disease potential in respiratory and dermatology WIN027 blocks 2 well-validated [...]
Precision Medicine Portfolio Update: Illuccix China Phase 3 Study, TLX101-CDx and TLX250-CDx FDA Resubmissions
21/12/2025
MELBOURNE, Australia and INDIANAPOLIS, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today provides a precision medicine portfolio update in relation to: TLX591-CDx ( [...]
What Is the Best GLP-1 Supplement for Weight Loss? Industry Analysis Reveals Probiotic Akkermansia Formulas as Affordable Ozempic Alternatives
20/12/2025
Health Journey Addresses 'Best GLP-1 Supplement' Question with Akkermansia-Based Formula Analysis as Six-Month Costs Compare at $294-534 vs. $4,800-7,200 for Pharmaceutical GLP-1 LAKELAND, Dec. 20, 2025 (GLOBE NEWSWIRE [...]

Pages